MedTrace Logo

Transcranial Direct Current Stimulation in Offenders

NCT03036683 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2022-10-18

No results posted yet for this study

Summary

This study investigates the effect of upregulating prefrontal cortex activity on risk-taking, and antisocial and aggressive behavior in violent offenders. In the double-blind, randomized controlled trial, using a within-subject crossover design, each participant will undergo anodal transcranial direct current stimulation of the right dorsolateral prefrontal cortex and sham stimulation. After each stimulation session, neural activity and behavioral responses to tasks assessing risk-taking and aggressive behavior will be recorded. The effect of tDCS on violent offenders will also be assessed in comparison to age and gender-matched healthy controls.

Conditions

  • Aggression
  • Risk-Taking
  • Antisocial Behavior

Interventions

DEVICE

Transcranial direct current stimulation

Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).

DEVICE

Sham transcranial direct current stimulation

The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.

Sponsors & Collaborators

  • RWTH Aachen University

    collaborator OTHER

  • Olivia Choy

    lead OTHER

Principal Investigators

  • Ute Habel, PhD · RWTH Aachen University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2021-06-01
Completion
2022-06-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03036683 on ClinicalTrials.gov